The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects

References

• Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009;15(Suppl 1):9s–16s. doi:10.1177/1076029609343004
   PubMed Web of Science ®Google Scholar
• Ahmed S, Levin V, Malacoff R, Martinez MW. Dabigatran: a new chapter in anticoagulation. Cardiovasc Hematol Agents Med Chem. 2012;10(2):116–123. doi:10.2174/187152512800388911
   Google Scholar
• Armbruster AL, Buehler KS, Min SH, Riley M, Daly MW. Evaluation of dabigatran for appropriateness of use and bleeding events in a community hospital setting. Am Health Drug Benefits. 2014;7(7):376–384.
   Google Scholar
• Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9(11):2168–2175. doi:10.1111/j.1538-7836.2011.04498.x
   PubMed Web of Science ®Google Scholar
• Stangier J, Sthle H, Rathgen K, Roth W, Reseski K, Körnicke T. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin. J Clin Pharmacol. 2012;52(2):243–250. doi:10.1177/0091270010393342
   PubMed Web of Science ®Google Scholar
• Paré G, Eriksson N, Lehr T, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013;127(13):1404–1412. doi:10.1161/CIRCULATIONAHA.112.001233
   PubMed Web of Science ®Google Scholar
• Dimatteo C, Dimatteo C, D’Andrea G, et al. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res. 2016;144(p):1–5. doi:10.1016/j.thromres.2016.05.025
   Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363(19):1875–1876. doi:10.1056/NEJMc1007378
   PubMed Web of Science ®Google Scholar
• Kanuri SH, Kreutz RP. Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med. 2019;9(1):7. doi:10.3390/jpm9010007
   Web of Science ®Google Scholar
• Ross S, Pare G. Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran. Pharmacogenomics. 2013;14(13):1565–1572. doi:10.2217/pgs.13.149
   Web of Science ®Google Scholar
• Gao X, Yang YM, Zhu J, Dai Y, Tan HQ. [Dabigatran versus warfarin for the prevention of stroke in Chinese patients with nonvalvular atrial fibrillation: Chinese subpopulation analysis of RE-LY]. Zhonghua Xin Xue Guan Bing Za Zhi. 2016;44(11):929–934. Chinese. doi:10.3760/cma.j.issn.0253-3758.2016.11.006
   Google Scholar
• Gosselin RC, Adcock DM, Bates SM, et al. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost. 2018;118:437–450. doi:10.1055/s-0038-1627480
   PubMed Web of Science ®Google Scholar
• Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45(5):555–563. doi:10.1177/0091270005274550
   PubMed Web of Science ®Google Scholar
• Hartter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa(R)) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol. 2013;75:1053–1062. doi:10.1111/j.1365-2125.2012.04453.x
   PubMed Web of Science ®Google Scholar
• Pablo MSR, Dolores O, Marcos NG, et al. Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran. Adv Ther. 2020;37(8):3537–3550. doi:10.1007/s12325-020-01414-x
   Web of Science ®Google Scholar
• Chin PK, Wright DF, Zhang M, et al. Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C. Drugs R D. 2014;14(2):113–123. doi:10.1007/s40268-014-0045-9
   PubMedGoogle Scholar
• Hamzic S, Kummer D, Milesi S, et al. Novel genetic variants in carboxylesterase 1 predict severe early-onset capecitabine-related toxicity. Clin Pharmacol Ther. 2017;102(5):796–804. doi:10.1002/cpt.641
   PubMed Web of Science ®Google Scholar
• Sychev D, Skripka A, Ryzhikova K, et al. Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease. Drug Metab Pers Ther. 2020;35(1):254.
   Google Scholar
• Ji QY, Zhang CY, Xu Q, et al. The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation. Br J Clin Pharmacol. 2020. doi:10.1111/bcp.14646
   Web of Science ®Google Scholar
• Shi J, Wang X, Nguyen J-H, et al. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem Pharmacol. 2016;119:76–84. doi:10.1016/j.bcp.2016.09.003
   PubMed Web of Science ®Google Scholar
• Sychev DA, Nikolaevich LA, Shelekhova TV, et al. The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty. Pharmgenomics Pers Med. 2018;11:127–137. doi:10.2147/PGPM.S169277
   PubMed Web of Science ®Google Scholar
• Gouin-Thibault I, Delavenne X, Blanchard A, et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thromb Haemost. 2017;15(2):273–283. doi:10.1111/jth.13577
   PubMed Web of Science ®Google Scholar